(Q79236644)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17039634%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

title

Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17039634%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

1 reference

1 reference

metastatic colon cancer

1 reference

1 reference

David Barnett

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17039634%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Andrew Stevens

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17039634%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Carole Longson

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17039634%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

publication date

1 October 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17039634%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

20 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17039634%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17039634%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17039634%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

807-808

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17039634%20AND%20SRC:MED&resulttype=core&format=json

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

20 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970898-1

7 January 2021

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970898-1

7 January 2021

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970898-1

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970898-1

7 January 2021

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970898-1

7 January 2021

10.1016/S1470-2045(06)70898-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17039634%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference